Warren-based Tevogen Bio took significant steps toward expanding R&D and manufacturing capabilities. In an announcement on Tuesday, CD8 Technology committed to providing a $50 million, turn-key facility to Tevogen on a first-priority basis for its manufacturing needs to develop off-the-shelf, genetically unmodified T-cell therapeutics to treat infectious disease and cancers.
Tevogen announced a $1b+ forecast earlier this month and through this facility, should be able to realize its revenue potential.
The proposed facility is intended to support both pre-clinical research and GMP manufacturing capabilities, staffed by Tevogen.
“By overcoming significant capital and time barriers of entry needed to build GMP capabilities at scale, this venture is expected to significantly expedite both research and manufacturing,” Ryan Saadi, CEO of Tevogen Bio, said. “This facility will be instrumental in advancing our mission to bring innovative solutions to market with speed and cost efficiency.”
This development is part of Tevogen’s strategy to grow its immunotherapy offerings without impacting shareholder equity.
